![Philip Nickson](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Philip Nickson
Generell Rådgivare på
MONTE ROSA THERAPEUTICS, INC.
Förmögenhet: 908 600 $ per 2026-07-31
Profil
Philip Nickson is currently Chief Business & Legal Officer at Monte Rosa Therapeutics, Inc. since 2024.
Previously, Dr. Nickson was Vice President-Intellectual Property at Momenta Pharmaceuticals, Inc. from 2012 to 2021.
Education includes a doctorate from The University of Manchester and a graduate degree from Suffolk University.
Kända innehav i offentliga företag
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
| 2026-04-09 | 55 000 ( 0,07 % ) | 908 600 $ | 2026-07-31 |
Aktiva positioner av Philip Nickson
| Företag | Position | Start |
|---|---|---|
| MONTE ROSA THERAPEUTICS, INC. | Generell Rådgivare | 2021-03-01 |
Tidigare kända positioner av Philip Nickson
| Företag | Position | Slut |
|---|---|---|
| MOMENTA PHARMACEUTICALS, INC. | Företagsledare/Principal | 2021-03-01 |
Philip Nicksons utbildningar
Erfarenheter
Innehade positioner
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Relationer
58
Första gradens relationer
4
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
Kopplade företag
| Privata företag | 4 |
|---|---|
Momenta Pharmaceuticals, Inc.
 Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that discovers and develops novel biologic therapies for the treatment of rare immune-mediated diseases | Health Technology |
The University of Manchester
 The University of Manchester Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Suffolk University
 Suffolk University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Monte Rosa Therapeutics, Inc.
 Monte Rosa Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops molecular glue degrader medicines for oncology, autoimmune and inflammatory diseases | Health Technology |
